dicaffeoyl-meso-tertaric acid | 133520-29-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dicaffeoyl-meso-tertaric acid
• 英文别名: 2,3-O-dicaffeoyltartaricacid；meso-dicaffeoyltartaric acid；trans-chicoric acid；meso-di-O-caffeoyltartaric acid；O,O'-bis-(3,4-dihydroxy-trans-cinnamoyl)-meso-tartaric acid；O,O'-Bis-(3,4-dihydroxy-trans-cinnamoyl)-mesoweinsaeure；(2S,1R)-1,2-Bis(3-(3,4-dihydroxyphenyl)prop-2-enoyloxy)ethane-1,2-dicarboxylic acid；(2R,3S)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
• CAS: 133520-29-3
• 化学式: C₂₂H₁₈O₁₂
• 分子量: 474.378
• InChiKey: YDDGKXBLOXEEMN-XAKUNQSDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  208
• 氢给体数：
  6
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  酒石酸 、 alkaline earth salt of/the/ methylsulfuric acid 生成 dicaffeoyl-meso-tertaric acid
  参考文献：
  名称：

  菊苣酸（dicaffeyltartic酸）：其从菊苣（隔离Chicorium苣）和合成

  摘要：

  描述了一种从菊苣叶的水煎剂中分离出新的旋光性结晶物质的方法，为此提出了名称菊苣酸。实验证据表明其结构为立果酒石酸的咖啡酸二酯，这是自然界中首次以（-）形式发现的二酯。它的合成以及催乳和旋光异构体的合成分别受羰基咖啡酸氯化物对d（-）-，l（+）-和内消旋酒石酸的影响。

  DOI：

  10.1016/0040-4020(58)88005-9

文献信息

• Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
  申请人：Robinson W. Edward

  公开号：US20050049242A1

  公开（公告）日：2005-03-03

  The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity in vitro and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. The novel compounds disclosed include 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine. Tests of integrase inhibitors with 2′,3′-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant.

  本发明包括一组新颖的化合物，已被证明能够在体外强力且选择性地抑制HIV整合酶（IN）活性，并在非毒性浓度下有效抑制活体培养细胞中的HIV复制。所披露的新颖化合物包括2,3-二（3,4-二羟基-二羟基二羟基肉桂酰）-L-酒石酸，2,3-二（3,4-二羟基苯甲酰）-L-酒石酸，2,3-二（3,4-二羟基苯乙酰）-L-酒石酸，2,3-二（3,4,5-三羟基苯甲酰）-L-酒石酸，2,3-二咖啡酰二氨基丙酸，1,2-二咖啡酰-L-甘油酸，双-3,4-二咖啡酰二氨基苯甲酸，二-3,4-二羟基苯乙烯琥珀酸，二-3,4-二羟基二羟基苯乙烯琥珀酸，2,3-二咖啡酰-L-丝氨酸，双咖啡酰-L-异丝氨酸和1,4-二咖啡酰-L-赖氨酸。对整合酶抑制剂与2′,3′-二脱氧胞苷、阿司匹林和奈非那韦（蛋白酶抑制剂）的测试表明，对逆转录酶抑制剂耐药病毒具有强大的协同作用。将整合酶抑制剂添加到联合药物疗法中的潜在益处是显著的。
• Methods for altering levels of phenolic compounds in plant cells
  申请人：Stiftung Caesar Center of Advanced European Studies and Research

  公开号：EP1671535A1

  公开（公告）日：2006-06-21

  The present invention provides a plant derived extract comprising inhibitory activity against HIV integrase, wherein the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract. Furthermore, methods and materials for altering levels in plants of one or more phenolic compounds that are intermediates or final products of the plant phenylpropanoid pathway are described. In addition, methods for the isolation of enzymes and their encoding genes, which are involved in the biosynthesis of selected phenolic compounds such as depsides are provided as well as transgenic organisms transformed therewith.

  本发明提供了一种植物提取物，该提取物包含对 HIV 整合酶的抑制活性，其中，在形成提取物之前，可通过对植物施压来增加提取物中抑制活性的量。此外，本发明还描述了改变植物中一种或多种酚类化合物水平的方法和材料，这些酚类化合物是植物苯丙醇途径的中间产物或最终产物。此外，还提供了分离酶及其编码基因的方法，这些基因参与了所选酚类化合物（如去苷类）的生物合成，还提供了用其转化的转基因生物。
• NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS
  申请人：The Regents of the University of California

  公开号：EP1063888A1

  公开（公告）日：2001-01-03
• ANTI-DIABETES COMPOSITION CONTAINING CHICORIC ACID AND/OR ONE OF THE METABOLITES THEREOF
  申请人：Andary Claude

  公开号：US20110015140A1

  公开（公告）日：2011-01-20

  The present invention relates to the use of chicoric acid and/or at least one of these metabolites selected among mono-caffeoyl-tartaric acid and/or m-hydroxyphenylpropionic acid, and/or 4-vinylcatechol and/or 4-ethylcatechol for manufacturing a composition intended for prevention or treatment in an insulin-resistant patient or hypoinsulinemia and/or associated pathologies.
• STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS
  申请人：CARGILL, INCORPORATED

  公开号：US20190223481A1

  公开（公告）日：2019-07-25

  A solubilized steviol glycoside composition including one or more steviol glycosides and one or more steviol glycoside solubility enhancers can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, pharmaceuticals, nutraceuticals, and the like.